Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

CTI BIOPHARMA CORP (CTI)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsDec-31-22Sep-30-22Jun-30-22Mar-31-22Dec-31-21Sep-30-21Jun-30-21Mar-31-21
   10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Net product sales  21.118.212.32.3    
Operating costs and expenses:          
Cost of sales  1.21.20.90.3    
Research and development  11.98.28.78.010.79.79.39.4
Selling, general and administrative  23.721.521.618.024.713.710.27.6
Other operating expenses  -2.1-0.4 11.0    
    Total operating costs and expenses  34.730.531.237.435.423.419.517.1
    Loss from operations  -13.6-12.2-18.9-35.1-35.4-23.4-19.5-17.1
            Operating margin  -64.5%-67.0%-153.2%-1529.4%    
   
Non-operating expenses:          
Interest expense, net  -3.8-3.6-3.8-2.1-1.4-0.7-0.2-0.2
Other non-operating expenses  -0.10.1  0.0-0.1  
    Total non-operating expenses  -3.9-3.5-3.8-2.1-1.4-0.8-0.2-0.2
    Net loss  -17.5-15.7-22.7-37.2-36.8-24.2-19.7-17.3
   
Net loss per common share: Basic (in dollars per share)  ($0.12)($0.13)($0.21)($0.37)($0.39)($0.26)($0.21)($0.23)
Net loss per common share: Diluted (in dollars per share)  ($0.12)($0.13)($0.21)($0.37)($0.39)($0.26)($0.21)($0.23)
   
Shares used in calculation of net loss per common share, basic (in shares)  114.7121.6108.599.890.193.892.376.4
Shares used in calculation of net loss per common share, diluted (in shares)  114.7121.6108.599.890.193.892.376.4

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy